FluoroPharma Medical, Inc.: 10-Q filed 2016-08-15
What FluoroPharma Medical, Inc. reported in its quarterly report filed 2016-08-15 (fiscal Q2 2016): 24 published measures, 67 facts as tagged in accession 0001415889-16-006837.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-08-15
- Fiscal period
- fiscal Q2 2016
- Accession
- 0001415889-16-006837 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All FluoroPharma Medical, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 772,584 | USD | |
| At 2015-12-31 | 838,598 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | -10,188,819 | USD | |
| At 2015-12-31 | -7,860,383 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 408,309 | USD | |
| At 2015-12-31 | 290,847 | USD | |
| At 2015-06-30 | 42,042 | USD | |
| At 2014-12-31 | 252,145 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -734,100 | USD | 91 |
| 2016-01-01 to 2016-06-30 | -2,306,734 | USD | 182 |
| 2015-04-01 to 2015-06-30 | -1,428,040 | USD | 91 |
| 2015-01-01 to 2015-06-30 | -2,002,136 | USD | 181 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-06-30 | -233,845 | USD | 182 |
| 2015-01-01 to 2015-06-30 | -781,258 | USD | 181 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-06-30 | 352,600 | USD | 182 |
| 2015-01-01 to 2015-06-30 | 535,185 | USD | 181 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-06-30 | -1,293 | USD | 182 |
| 2015-01-01 to 2015-06-30 | 35,970 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | -35,176,875 | USD | |
| At 2015-12-31 | -32,604,374 | USD |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -0.03 | USD/shares | 91 |
| 2016-01-01 to 2016-06-30 | -0.08 | USD/shares | 182 |
| 2015-04-01 to 2015-06-30 | -0.05 | USD/shares | 91 |
| 2015-01-01 to 2015-06-30 | -0.08 | USD/shares | 181 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 9,863 | USD | |
| At 2015-12-31 | 11,049 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -679,367 | USD | 91 |
| 2016-01-01 to 2016-06-30 | -1,361,338 | USD | 182 |
| 2015-04-01 to 2015-06-30 | -705,187 | USD | 91 |
| 2015-01-01 to 2015-06-30 | -1,566,228 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 463,672 | USD | |
| At 2015-12-31 | 509,002 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 456,031 | USD | 91 |
| 2016-01-01 to 2016-06-30 | 855,107 | USD | 182 |
| 2015-04-01 to 2015-06-30 | 80,822 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 157,924 | USD | 181 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 10,961,403 | USD | |
| At 2015-12-31 | 8,698,981 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 1,400,464 | USD | |
| At 2015-12-31 | 1,219,867 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 299,049 | USD | |
| At 2015-12-31 | 318,547 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 679,367 | USD | 91 |
| 2016-01-01 to 2016-06-30 | 1,361,338 | USD | 182 |
| 2015-04-01 to 2015-06-30 | 705,187 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 1,566,228 | USD | 181 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 239,667 | USD | 91 |
| 2016-01-01 to 2016-06-30 | 429,327 | USD | 182 |
| 2015-04-01 to 2015-06-30 | 102,801 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 285,206 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 33,648,780 | shares | |
| At 2015-12-31 | 32,908,503 | shares |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 232,235 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -866,998 | USD | 91 |
| 2016-01-01 to 2016-06-30 | -2,572,501 | USD | 182 |
| 2015-04-01 to 2015-06-30 | -1,572,662 | USD | 91 |
| 2015-01-01 to 2015-06-30 | -2,289,653 | USD | 181 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 439,700 | USD | 91 |
| 2016-01-01 to 2016-06-30 | 932,011 | USD | 182 |
| 2015-04-01 to 2015-06-30 | 602,386 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 1,281,022 | USD | 181 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -54,733 | USD | 91 |
| 2016-01-01 to 2016-06-30 | -945,396 | USD | 182 |
| 2015-04-01 to 2015-06-30 | -722,853 | USD | 91 |
| 2015-01-01 to 2015-06-30 | -435,908 | USD | 181 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-06-30 | 223,409 | USD | 182 |
| 2015-01-01 to 2015-06-30 | 606,631 | USD | 181 |
Inspect the source
- Entity
- FluoroPharma Medical, Inc. / CIK 0001402785
- Captured
- SEC response SHA-256
4d77d986a03178d60883d667e91c227ed829415c26872c73ee7ae0df9851ff14
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001402785.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))